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Human exposureContributions of direct and indirect (via precursors) pathways of human exposure to perﬂuorooctane sulfonic
acid (PFOS) isomers and perﬂuoroalkyl carboxylic acids (PFCAs) are estimated using a Scenario-Based Risk
Assessment (SceBRA) modelling approach. Monitoring data published since 2008 (including samples from
2007) are used. The estimated daily exposures (resulting from both direct and precursor intake) for the general
adult population are highest for PFOS and perﬂuorooctanoic acid (PFOA), followed by perﬂuorohexanoic acid
(PFHxA) and perﬂuorodecanoic acid (PFDA), while lower daily exposures are estimated for perﬂuorobutanoic
acid (PFBA) and perﬂuorododecanoic acid (PFDoDA). The precursor contributions to the individual
perﬂuoroalkyl acid (PFAA) daily exposures are estimated to be 11–33% for PFOS, 0.1–2.5% for PFBA, 3.7–34%
for PFHxA, 13–64% for PFOA, 5.2–66% for PFDA, and 0.7–25% for PFDoDA (ranges represent estimated precursor
contributions in a low- and high-exposure scenario). For PFOS, direct intake via diet is the major exposure path-
way regardless of exposure scenario. For PFCAs, the dominant exposure pathway is dependent on perﬂuoroalkyl
chain length and exposure scenario. Modelled PFOS and PFOA concentrations in human serumusing the estimat-
ed intakes from an intermediate-exposure scenario are in agreement with measured concentrations in different
populations. The isomer pattern of PFOS resulting from total intakes (direct and via precursors) is estimated to be
enriched with linear PFOS (84%) relative to technical PFOS (70% linear). This ﬁnding appears to be contradictory
to the observed enrichment of branched PFOS isomers in recent human serummonitoring studies and suggests
that either external exposure is not fully understood (e.g. there are unknown precursors, missing or poorly
quantiﬁed exposure pathways) and/or that there is an incomplete understanding of the isomer-speciﬁc
human pharmacokinetic processes of PFOS, its precursors and intermediates.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Per- and polyﬂuoroalkyl substances (PFASs) are chemicals that have
been used for industrial applications and in consumer products since
the 1950s (Buck et al., 2011). Perﬂuorooctane sulfonic acid (PFOS),
and related chemicals such as N-methyl and N-ethyl perﬂuorooctane
sulfonamido ethanols (Me- and EtFOSEs) and -sulfonamides (Me- and
EtFOSAs) have been manufactured by electrochemical ﬂuorination
(ECF) as a mixture of linear (70%) and branched (30%) isomers
(Martin et al., 2010). Production of PFOS and related chemicals was
phased out in North America and Europe in 2002 by its main producer.
Perﬂuoroalkyl carboxylic acids (PFCAs) have been manufactured
by both ECF (producing both linear and branched isomers) and
telomerization processes (producing only linear isomers), andmajor in-
dustrial companies have committed to reduce production and eliminate6 8674 7638.
ink).
. This is an open access article underemissions of PFCAs with a chain length ≥ C8, and other chemicals that
can degrade to these long-chain PFCAs by 2015 (US EPA, 2006).
Human biomonitoring studies have shown that the general popula-
tion in several countries has been exposed to perﬂuoroalkyl acids
(PFAAs) such as PFOS and PFCAs, as well as to numerous precursors
for several decades and that this exposure has changed over time
(Glynn et al., 2012; Lee and Mabury, 2011; Loi et al., 2013; Yeung
et al., 2013a,b). Ingestion of dust, food, drinking water and inhalation
of air have all been identiﬁed as human exposure pathways (De Silva
et al., 2012; Filipovic and Berger, in press; Gebbink et al., submitted for
publication; Shoeib et al., 2011). PFOS and PFOA exposure of the general
population has previously been estimated (Trudel et al., 2008), and in a
later study the role of precursor exposure was estimated in human ex-
posure to PFOS and PFOA (Vestergren et al., 2008). Human exposure
to PFOS and PFCAs via one ormultiple exposure pathways is considered
as direct exposure, while exposure to their precursors and subsequent
biotransformation of these precursors to PFOS and PFCAs is considered
as indirect exposure to PFOS and PFCAs. Precursors that can act as an in-
direct exposure source to PFOS (i.e. they are biotransformed in humans)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sulfonamidoacetic acids (FOSAAs) (Tomy et al., 2004; Xie et al., 2009;
Xu et al., 2004). Chemicals that can be biotransformed to PFCAs in
humans include ﬂuorotelomer-based chemicals such as ﬂuorotelomer
alcohols (FTOHs) and FTOH-based polyﬂuoroalkyl phosphate esters
(PAPs) (D'Eon and Mabury, 2011; Martin et al., 2005).
For adults, direct exposure to PFOS and PFOA was estimated by
Vestergren et al. (2008) to contribute N92% to the total intake of these
two chemicals in a low- and intermediate-exposure scenario, whereas
in a high-exposure scenario precursors contributed 50–60% to the
total PFOS and PFOA exposure. Direct exposure via diet was estimated
to be a major exposure pathway; however, the dietary contribution to
the estimated intakes was likely overestimated. Using an improved
analytical method, Vestergren et al. (2012) later showed that PFOS
and PFOA concentrations in food samples had previously been
overestimated by an order of magnitude. Since 2008 more literature
data have become available on PFAAs and precursors in exposure
media. Precursors to C4, 6, 8, 10, 12 PFCAs, such as 4:2–12:2 FTOHs and
PAPs have been reported in exposure media (De Silva et al., 2012;
Gebbink et al., submitted for publication; Langer et al., 2010), however,
how much these precursors contribute to human PFCA exposure as an
indirect exposure pathway has so far not been investigated. Also, tem-
poral trend studies have reported on declining PFAA and precursor con-
centrations in food (Gebbink et al., submitted for publication; Ullah
et al., 2014). Based onmammal studies, exposure to PFAAs could result
in hepatotoxic, developmental, immunotoxic, and hormonal effects
(Lau et al., 2007).
In human serum samples, the PFOS isomer pattern has been report-
ed to varywidely, containing between 17% and 52%branched isomers of
total PFOS. However, serum samples generally contain a higher
percentage of branched isomers relative to linear PFOS compared to
ECF isomer pattern (30% sum branched isomers of total PFOS)
(Beesoon et al., 2011; Glynn et al., 2012; Gützkow et al., 2012;
Karrman et al., 2007; Rylander et al., 2009; Zhang et al., 2013b). The
mechanisms or processes causing this enrichment of branched isomers
in blood are not fully understood. In rats and humans, isomer-speciﬁc
differences in uptake and elimination rates for linear and branched
PFOS isomers have been observed (Benskin et al., 2009a; De Silva
et al., 2009; Zhang et al., 2013a). Also, reported differences in biotrans-
formation rates of branched and linear precursor isomers could inﬂu-
ence the PFOS isomer pattern (Benskin et al., 2009b; Peng et al.,
2014). PFOS and/or precursor isomers have been identiﬁed and quanti-
ﬁed in several human exposure media; however, the data are still limit-
ed. PFOS isomer patterns have been reported in dust, food, and drinking
water, while for PFOS precursors only the FOSA isomer pattern was re-
ported in drinking water (Beesoon et al., 2011; Filipovic and Berger, in
press; Gebbink et al., submitted for publication). To date, there is no in-
formation available regarding the overall PFOS isomer pattern humans
are exposed to via multiple direct and indirect exposure pathways.
Studies have shown that branched PFOS isomers affect genes in avian
species to a greater extent than the linear isomer (O'Brien et al., 2011).
In this studywe tested the following hypotheses: i) based on tempo-
ral trend monitoring studies the estimated human exposure to PFOS
and PFOA is lower, and the indirect intake is relatively more important
compared to previous estimations, ii) given that PFOA is the dominant
PFCA in human serum, estimated total intakes for other PFCA homo-
logues (perﬂuorobutanoic acid (PFBA), perﬂuorohexanoic acid
(PFHxA), perﬂuorodecanoic acid (PFDA) and perﬂuorododecanoic acid
(PFDoDA)) are lower than PFOA, and contributions of direct versus
indirect exposure vary widely by homologue, and iii) the PFOS isomer
pattern in total PFOS intake can help to explain the isomer pattern
observed in human serum. The direct and indirect intakes of PFAAs
and precursors are estimated through four major exposure pathways
(ingestion of dust, dietary and drinking water intake, and inhalation of
air) using the latest monitoring data that have become available since
2008 (including samples from 2007).2. Methodology
2.1. Modelling
The approach used here to estimate the indirect (precursor) contri-
bution to PFOS and PFCA exposure has been previously described by
Vestergren et al. (2008) and uses Scenario-Based Risk Assessment
(SceBRA) modelling (Trudel et al., 2008). The methodology deﬁnes
typical low-exposure, intermediate-exposure, and high-exposure to
chemicals of the general adult population through multiple pathways.
The 5th percentile, median, and 95th percentile of each input parameter
are used to represent the low-, intermediate-, and high-exposure
scenarios, respectively. The low-exposure scenario represents a “best
case” scenario with respect to human exposure to PFAAs, whereas
the high-exposure scenario represents a “worst case” scenario. Fig. 1
shows the concept of the estimation of precursor contribution to PFOS
and PFCA exposure, and the PFAAs and precursors that are included in
this study (see Table S1 for PFAA and precursor chemical structures).
In this study, peer-reviewed data are included that were published
after the study by Vestergren et al. (2008). This includes samples that
were taken during and after 2007. There have been signiﬁcant advances
in analysis of PFAAs and their precursors in exposure media in recent
years (e.g. increased instrument sensitivity and improved understand-
ing of contamination issues) (Berger et al., 2011). Therefore, the use of
recent data will not only allow for an assessment of the recent exposure
situation but will also allow for a more accurate assessment. Certain
PFAAs and precursors were phased out in North America and Europe
in 2002, however, they are still produced in some continental Asian
countries, especially China (Wang et al., 2014). Therefore, only litera-
ture data of samples collected in North America, Europe, Korea, and
Japan are included in this study, representing exposure to PFAAs and
precursors of the general adult population in industrial countries in
the northern hemisphere with similar histories of production and use
of PFAS products. Blood serum concentrations of PFCAs in industrial
countries (e.g. USA, Europe, and Japan) are similar, and proﬁles and
temporal trends are also similar (Vestergren and Cousins, 2009). This
suggests similar exposure to PFAAs in these countries.
In order to determinewhich parametersweremost inﬂuential in the
intake estimations, the sensitivity (S) is calculated as the change in the
output (ΔO/O) as a result of changing input values (I) by a small ﬁxed
amount (ΔI). Every input parameter is increased by 1%, thus (ΔI/I) =
0.01.
S ¼ ΔO=Oð Þ
ΔI=I
2.2. Routes of exposure, uptake factors and biotransformation factors
The following human exposure pathways are included in this study:
ingestion of dust, food, and drinking water, and inhalation of air.
Vestergren et al. (2008) considered additional exposure pathways asso-
ciatedwith consumer products such as contact with treated clothes and
impregnation sprays, however, these pathways played an insigniﬁcant
role in the overall exposure to PFOS, PFOA, and their precursors and
are therefore not considered in the present study. For each of the path-
ways considered, intakes are estimated on a per-day basis normalized to
body weight (i.e. intakes in units of pg/kg/d). To calculate the contribu-
tion of precursors to total PFAA exposure, concentrations of precursors
are converted to their respective PFAAs on a molar basis, and in the
case of a diPAP with twice the same chain length (e.g., 6:2/6:2 diPAP)
the molar concentration is multiplied by two. A summary of the
employed literature data of PFAA and precursor concentrations (5th
percentile, median, and 95th percentile) measured in dust, air, food,
and drinkingwater can be found in Tables S2–S6. A detailed description
of the intake estimations for each exposure pathway can also be found
in the Supplementary data.
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Fig. 1. Schematic of direct and indirect (precursor) exposure pathways for PFOS and PFCAs.
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were calculated as the fraction of an oral dose recovered in tissues or
blood. Uptake factors for the low-, intermediate-, and high-exposure
scenarios were previously estimated to be 0.66, 0.80, and 0.91, respec-
tively, for PFOA and PFOS (Trudel et al., 2008). These uptake factors
were used for PFOS precursors by Vestergren et al. (2008) due to lack
of rodent data for PFOS precursors and are used in the present study.
Uptake factors for FTOH were previously reported as 0.27, 0.38, and
0.56, respectively (based on various in vivo and in vitro studies), for
the three exposure scenarios (Vestergren et al., 2008) and these values
are used in the present study. Due to lack of information for other PFCAs,
we use the same uptake factors as for PFOS and PFOA. For diPAPs, the
bioavailability in rats was reported to be highly variable depending on
the chain length (D'Eon and Mabury, 2011). For example, the bioavail-
ability for 4:2/4:2 diPAP was estimated to 190%, whereas for 10:2/10:2
diPAP the bioavailability could not be calculated because it was not
observed in the blood after dosing. The 10:2/10:2 diPAP was, however,
reported to be bioavailable to humans as it was detected in human
blood samples (D'Eon et al., 2009; Yeung et al., 2013a). As these reports
do not give a coherent picture of diPAP uptake factors, the assumption is
made here that uptake factors for all diPAPs are the same as for the
PFAAs, i.e. 0.66, 0.80, and 0.91 for the three exposure scenarios, respec-
tively. The previously reported bioavailability in rats for the 6:2/6:2
diPAP is therewith comparable with the assumed uptake factor in the
intermediate scenario of the present study. For exposure through inha-
lation the assumption is made that there is complete absorption of the
PFAAs and precursors (Vestergren et al., 2008).
Biotransformation of PFOS precursors (EtFOSE and FOSA) to PFOS
has been observed in in vivo experiments in rats with reported biotrans-
formation factors of 0.095, 0.20 and 0.32 (Seacat, 2000; Seacat et al.,
2003; Xie et al., 2009), however, the biotransformation of FOSA to
PFOS is likely greater (reported as N0.32), as discussed by Martin et al.
(2010). These factors represent the variation of biotransformation fac-
tors of precursors to PFOS. As there is no further literature data on bio-
transformation factors of PFOS precursors, we use these factors for all
PFOS precursors in the low-, intermediate-, and high-exposure
scenarios, respectively. Biotransformation of ﬂuorotelomer-based
compounds (FTOH and PAPs) has been shown to produce multiple
PFCAs in in vivo and in vitro studies, however, metabolism of e.g. 8:2
FTOH or 8:2/8:2 diPAP produced predominantly PFOA and only to a
minor extent other chain length PFCAs, such as PFNA (D'Eon and
Mabury, 2011; Martin et al., 2005). Therefore, odd carbon numberPFCAs are not included in this study. We make the assumption that
4:2-telomer based precursors are metabolized only to PFBA, 6:2-
telomer based precursors to PFHxA, 8:2-telomer based precursors
to PFOA, 10:2-telomer based precursors to PFDA, and 12:2-telomer
based precursors to PFDoDA. Biotransformation factors for FTOHs
were earlier estimated by Vestergren et al. (2008) based on literature
data as 0.0002, 0.005, and 0.017 for the low-, intermediate-, and high-
exposure scenarios, respectively. These factors represent the variation
of biotransformation factors of telomer based precursors to PFCAs. Bio-
transformation factors for diPAPs have been determined using rats, and
were shown to be chain-length dependent (D'Eon and Mabury, 2011).
DiPAPs with a chain length ≤6:2/6:2 had a biotransformation factor of
0.01, while longer chain length (N6:2/6:2) diPAPs had biotransforma-
tion factors around 0.1. These biotransformation factors were used in
the intermediate-exposure scenario. As there is no additional literature
data available, biotransformation factors for diPAPs in the low-, and
high-exposure scenario are chosen as a factor of 10 lower and higher,
respectively, compared to the intermediate-exposure scenario. All the
model input parameters for estimating the precursor contribution to
PFOS and PFCA exposure in the three exposure scenarios are provided
in Tables S7–S9 in the Supplementary data.
2.3. Estimating the isomer pattern of total PFOS exposure
Several studies have reported isomer patterns of PFOS and its pre-
cursors in different exposure media (Table S10). In Canadian dust sam-
ples collected in 2007–2008, Beesoon et al. (2011) reported an isomer
pattern of 70% linear and 30% branched PFOS isomers. Although PFOS
precursors were detected in the dust samples, no information regarding
isomer patterns was provided for these chemicals. Therefore, the basic
assumption is made here that the isomer ratio of precursors in dust
was 70% linear and 30% branched. However, additional scenarios with
varying linear/branched isomer ratios of precursors in dust are also
discussed in Section 3.2 including Fig. 4 below. Gebbink et al.
(submitted for publication) reported the PFOS isomer pattern in food
homogenates representing the general Swedish diet in 2010 as 92% lin-
ear and 8% sum branched PFOS. In these same food samples, branched
FOSAwas below detection limit, but using half the detection limit as hy-
pothetical branched FOSA concentration, a ratio of 98% linear and 2%
branched FOSAwas estimated. PFOS and FOSA isomer patterns in drink-
ing water collected from several European countries were comparable,
i.e., 60% linear PFOS and 58% linear FOSA (Filipovic and Berger, in
163W.A. Gebbink et al. / Environment International 74 (2015) 160–169press; Ullah et al., 2011). In outdoor air samples, Jahnke et al. (2007)
reported linear to branchedGC/MS patterns forMeFOSE thatwere com-
parable to an ECF standard (although isomers were not quantiﬁed);
therefore, the basic assumption is made here that PFOS and precursor
isomer ratios in air samples are 70/30 linear/branched. Nevertheless,
the isomer ratio of both PFOS and its precursors is also varied in differ-
ent scenarios. Intermediate-exposure scenario parameters are used in
order to determine the PFOS isomer pattern that the general adult pop-
ulation is exposed to through the above mentioned pathways. For
isomer-speciﬁc biotransformation factors and uptake factors different
scenarios are discussed in Section 3.2 and in Fig. 4 below. Exposure to
linear and branched isomers of PFCAs produced by ECF is not estimated
in this study as literature data on PFCA isomers in human exposure
pathways is not available or extremely limited.
2.4. Estimating serum PFAA concentrations based on total intakes
Human serum PFAA concentrations are dependent on the pharma-
cokinetic parameters for the PFAAs as well as the intake rate. Serum
concentrations are estimated using a 1st order one-compartment
pharmacokinetic (PK) model. The model predicts PFAA serum concen-
trations as a function of the dose, elimination rate, and volume of distri-
bution, and has been described by Thompson et al. (2010). For the dose
estimates, the daily PFAA exposures from direct and indirect intake are
used from the intermediate-exposure scenario (Table 1). For PFBA and
PFHxA elimination rates (T½) and volumes of distribution (Vd), are
taken from Chang et al. (2008) and Russell et al. (2013) (PFBA: T½ =
0.0086 y, Vd = 220 mL/kg; PFHxA: T½ = 0.088 y, Vd = 200 mL/kg).
Several studies have estimated elimination half-lives for PFOS and
PFOA (Bartell et al., 2010; Brede et al., 2010; Olsen et al., 2007; Wong
et al., 2014) and of these reported elimination half-lives the highest
and lowest are used to estimate a range of serum concentrations
(PFOS:min=4.2 y, max=5.4 y; PFOA:min=2.3 y,max=3.8 y). Vol-
umes of distribution for PFOS and PFOA are estimated as 230 and
170 mL/kg, respectively (Thompson et al., 2010). For PFDA and PFDoDA
elimination half-lives and/or volumes of distribution are not available
and serum concentrations are therefore not estimated.
3. Results and discussion
3.1. Direct versus indirect exposure to PFOS
The estimated intakes for PFOS and all individual precursors (assum-
ing no biotransformation) are provided in Table S11. IncludingTable 1
Estimated daily exposures to PFOS and PFCA homologues (pg/kg/d) through direct and
indirect intake pathways.
PFAA Exposure pathway Exposure scenario
Low Intermediate High
PFOS Direct 79 350 1200
Indirect 10 65 690
Total 89 410 1900
PFBA Direct 6.3 19 180
Indirect 0.01 0.10 4.8
Total 6.3 19 190
PFHxA Direct 14 55 340
Indirect 0.54 7.9 170
Total 15 63 520
PFOA Direct 38 200 1100
Indirect 5.7 75 1900
Total 44 270 3000
PFDA Direct 23 48 230
Indirect 1.3 19 440
Total 24 67 660
PFDoDA Direct 22 48 130
Indirect 0.17 2.7 45
Total 23 51 180biotransformation of precursors, the daily exposures to total PFOS
(direct and indirect) are estimated as 89 pg/kg/d, 410 pg/kg/d, and
1900 pg/kg/d for the low-, intermediate-, and high-exposure scenarios,
respectively (Table 1, Fig. 2). Of these total PFOS exposures, the relative
importance of precursors increases from the low- (11%) to the high-
exposure scenario (33%), although the precursor contribution in the
high-exposure scenario might be underestimated (see section on PFOS
precursor biotransformation factors, Section 2.2) (Tables S12–S14).
The relative contribution of each individual intake pathway to the
total PFOS daily exposures is displayed in Fig. 3. Direct exposure to
PFOS through food consumption is found to be the dominant exposure
pathway in the low- and intermediate-exposure scenarios, 86% and
66%, respectively. In the high-exposure scenario, important sources of
PFOS still include direct exposure via diet (43%) but also direct exposure
via ingestion of drinking water (11%) and dust (13%) and precursor ex-
posure via air inhalation (19%) and dust ingestion (14%). The sensitivity
analysis reveals that the GI uptake fraction and PFOS concentration in
the diet are the most inﬂuential parameters affecting the total PFOS ex-
posure in all exposure scenarios (Fig. S1). The concentration of PFOS in
food is today well deﬁned with a large number of studies reporting on
PFOS in human diet, but there are only few animal studies reporting
the GI uptake fraction.
The estimated total PFOS exposures for all three scenarios are 1–2
orders of magnitude lower compared to estimates reported earlier for
adults (Fig. 2) (Trudel et al., 2008; Vestergren et al., 2008). Also, the
relative contribution of precursors to total PFOS exposure in the three
exposure scenarios differs from the earlier study by Vestergren et al.
(2008). In the present study, the precursor contribution in the low-
exposure scenario is higher and in the high-exposure scenario lower
compared to earlier estimations. However, the relative importance of
the different exposure pathways (e.g., diet, dust, air) in the three expo-
sure scenarios is comparable to earlier estimations (Vestergren et al.,
2008). The observed differences in total intakes and patterns between
the present and earlier estimations could be the result of several factors.
A major factor is the overall declining concentrations of PFOS and its
precursors in human diet (Gebbink et al., submitted for publication;
Johansson et al., 2014; Ullah et al., 2014) and potentially also in other
exposure media due to the phase out by 3 M in 2002. This is also
reﬂected in decreasing trends in human serum (Glynn et al., 2012;
Yeung et al., 2013b). However, these recent temporal changes in con-
centrations in PFOS and its precursors cannot fully explain the 1–2
orders of magnitude differences in intake estimates between the
present study and Vestergren et al. (2008). Another important factor
is the improvement of analytical methods resulting in more accurate
(i.e., generally lower) PFOS concentrations in the major exposure path-
way, food (Vestergren et al., 2012). Furthermore, different assumptions
are made for some parameters in the intake estimations in this study
compared to Vestergren et al. (2008). For example, Vestergren et al.
(2008) assumed biotransformation factors of PFOS precursors in the
low- and high-exposure scenarios as 0.01 and 1, respectively, whereas
in this study the lowest and highest biotransformation factors reported
in the literature are used for the low- and high-exposure scenarios,
i.e., 0.095 and 0.32, respectively. This can to a large extent explain the
differences found for the relative importance of precursors in the low-
and high-exposure scenarios between the two studies.
A total of seven PFOS precursors are included in the estimation of
precursor contribution to PFOS exposure via different exposure path-
ways. Among the four exposure pathways included in this study, litera-
ture data are available formost of the selected precursors in air and dust
samples. In studies monitoring PFASs in food and drinking water sam-
ples, data on precursors are limited to FOSA. Although other precursors
have been detected in speciﬁc food items (e.g., MeFOSAA and EtFOSAA
in herring collected in 2011) (Ullah et al., 2014), these precursors
were below the detection limit in food homogenates representing the
general diet in 2010 (Gebbink et al., submitted for publication). Expo-
sure to precursors other than FOSA via consumption of speciﬁc food
110
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Fig. 2. Estimated PFOS and PFOA daily exposures of adults (pg/kg/d) reported by Trudel et al. (2008), Vestergren et al. (2008), and the present study. The estimated exposures reported by
Vestergren et al. and the present study represent the sum of direct and indirect (precursor) intakes, while the estimation by Trudel et al. is only based on direct PFOS and PFOA exposure.
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etary contribution of precursors was estimated as b2% of the total PFOS
exposure (Fig. 3). Biomonitoring studies reported the presence of other
PFOS precursors in human blood that are not included in this study. For
examples, the German population was exposed to perﬂuorooctane
sulfonamidoethanol-based phosphate esters (SAmPAPs), although theWater
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Fig. 3. Relative contribution (%) of estimated direct and precursor intakes to total PFOS,
PFBA, PFHxA, PFOA, PFDA, and PFDoDA daily exposures via multiple pathways in the
low-, intermediate, and high-exposure scenarios.detection frequency and concentrations in human serum were low
(Yeung et al., 2013b). There have been no studies to date focusing on
the exposure pathways that contribute to the presence of SAmPAPs in
human blood.
Based on our estimated PFOS exposures, our initial hypothesis, that
PFOS exposures with up-to-date data would result in lower intakes
compared to earlier estimations, is veriﬁed. This change in total PFOS
exposures is in line with changes observed in temporal trend monitor-
ing studies. However, other factors, such as improvement of analytical
methods, contribute to lower estimated PFOS exposures. The hypothe-
sis that precursors are more important compared to earlier estimations
is accepted in the low- and intermediate-exposure scenario, however,
not in the high-exposure scenario. The rejection of the hypothesis in
the high-exposure scenario can to a large extent be explained by the
lower biotransformation factor used in this scenario compared to earlier
estimations (0.32 vs 1). There are still uncertainties in the estimation of
PFOS intakes as well as in the contribution of precursors. For example,
not all precursors included in this study have been reported in all expo-
sure media, and there are precursors which have not been investigated
in any of the human exposure pathways (e.g., SAmPAPs). Also, there are
still large uncertainties regarding uptake and biotransformation factors
for PFOS and individual precursors. A better understanding of these
parameters would allow for a more accurate estimate of precursor
intake as an indirect source of PFOS exposure.3.2. Exposure to linear and branched PFOS isomers
The isomer pattern (linear and sum branched isomers) of total
human exposure to PFOS is investigated using the intermediate-
exposure scenario with the assumptions regarding the PFOS and pre-
cursor isomer patterns in dust and air and regarding biotransformation
efﬁciency mentioned in Section 2.3. The isomer pattern of total PFOS
exposure including all investigated intake pathways is estimated as
84% linear and 16% sum branched isomers, which is largely inﬂuenced
by diet (especially ﬁsh, which is often enriched in linear isomers;
Ullah et al., 2014) being the most important exposure pathway for
PFOS (Fig. 3). Based on this estimate, the isomer pattern of total PFOS
exposure is strongly enriched with the linear isomer compared to
both ECF PFOS (70% linear) and the isomer pattern found in human
serum (48–83% linear) (Beesoon et al., 2011; Glynn et al., 2012;
Gützkow et al., 2012; Karrman et al., 2007; Rylander et al., 2009;
Zhang et al., 2013b). A considerable uncertainty in this estimation is
the isomer pattern of precursors in dust and of PFOS and precursors in
air samples. Therefore, the isomer pattern of total PFOS exposure is
also estimated according to different scenarios (Fig. 4A and B). Varying
165W.A. Gebbink et al. / Environment International 74 (2015) 160–169the isomer pattern of precursors in dust from 100% linear to 100%
branched isomers has only a minor effect on the isomer pattern of
total PFOS exposure, i.e., changing it from 85% to 81% linear PFOS
(Fig. 4A). Varying the isomer pattern of PFOS and precursors in air
from 100% linear to 100% branched isomers results in an overall de-
crease of the linear PFOS isomer from 88% to 75% (Fig. 4B). Regardless
of these two scenarios with up to 100% branched isomers in dust or
air, the isomer pattern of total PFOS exposure remains enriched with
linear PFOS compared to ECF PFOS or the isomer pattern generally
found in human serum. When comparing the estimated PFOS isomer
pattern of the total exposure based only on direct PFOS exposure
(Fig. 4A and B, red line) relative to PFOS and precursor exposure (blue
line), only a small deviation is seen, indicating that direct PFOS exposure
dominates the overall PFOS isomer pattern or that both pathways
(direct and indirect exposure) lead to a similar PFOS isomer pattern.
Additional uncertainties in estimating the PFOS isomer pattern of
the total exposure are differences in uptake and biotransformation
rates between linear and branched precursor isomers. Both in vivo and30
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Fig. 4. Estimated% linear isomer of total PFOS exposurebased ondirect PFOS intake (red line) an
of % linear isomer are made with varying linear/branched ratios of precursors in dust (A), var
fractions of branched precursors to branched PFOS (C and E), and varying uptake fractions for
of ECF PFOS, and the grey area represents the range of % linear PFOS reported in human serumin vitro experiments have shown that branched precursor isomers are
degraded faster relative to the linear isomer (Benskin et al., 2009b;
Peng et al., 2014; Ross et al., 2012), however, no isomer-speciﬁc
biotransformation factors have been provided. In the intermediate-
exposure scenario in the present study, the biotransformation fraction
of precursors to PFOS is estimated at 0.2 for both branched and linear
isomers. However, the inﬂuence of a potentially higher percentage
biotransformation of branched precursors to branched PFOS is further
investigated with the assumption that the PFOS and precursor isomer
pattern in dust and air are 70/30 linear/branched and equal uptake for
all isomers (Fig. 4C). With biotransformation factors of N0.2 for the bio-
transformation of branched precursors to branched PFOS (relative to 0.2
for the linear precursor isomers), the isomer pattern in total PFOS expo-
sure intake reﬂects the isomer pattern found in human serum.However,
human serum isomer patterns cannot be explained even when com-
plete biotransformation of branched precursors to branched PFOS is
assumed. For both PFOS and its precursors, faster uptake of branched
isomers relative to the linear isomers was observed in rats and ﬁsh30
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scenario in the present study, the uptake fractions of PFOS and its pre-
cursors are estimated at 0.8 for both branched and linear isomers. The
inﬂuence of a potentially higher uptake efﬁciency for branched isomers
compared to linear isomers is further investigated with the assumption
that the PFOS and precursor isomer pattern in dust and air are 70/30
linear/branched and biotransformation fractions are 0.2 (Fig. 4D).
Greater uptake of branched PFOS and precursors (N0.8) compared to
the linear isomers had little impact on the isomer pattern of total
PFOS intake. Completely efﬁcient uptake of branched isomers (relative
to 0.8 for linear isomers) only changed the isomer pattern of total
PFOS intake from 84% to 81% linear PFOS. In an extreme scenario, with
the assumption that the precursor isomer patterns in dust and PFOS
and precursors in air are 100% branched and that there is complete up-
take for branched isomers, an isomer pattern of total PFOS exposure that
covers the whole range of human serum isomer patterns is observed
with a biotransformation yield of branched isomers between 20% and
70% (Fig. 4E). This is, however, a highly improbable scenario as there
is evidence of both linear and branched precursor isomers being present
in air samples (Jahnke et al., 2007).
Faster uptake of branched PFOS and precursors compared to linear
PFOS and precursors, as was seen in rats and ﬁsh (Benskin et al.,
2009a; Peng et al., 2014) would result in an enrichment of branched
PFOS relative to linear PFOS. However, as increasing uptake efﬁciency
and thus uptake ratewas shown only to have little impact on the isomer
pattern of total PFOS intake, it seems unlikely that uptake of branched
isomers alone would result in isomer patterns that are enriched with
branched PFOS as seen in human sera. Faster biotransformation of
branched precursors relative to linear isomers (Benskin et al., 2009b)
as well as faster urinary elimination of linear precursors relative to
branched precursors in humans as was seen for FOSA (Zhang et al.,
2013a) would result in increasing formation of branched PFOS relative
to linear PFOS originating from indirect exposure. If thiswas a dominant
pathway inﬂuencing the isomer pattern in humans then enrichment of
branched PFOS would be expected relative to the isomer pattern of the
total exposure. However, as discussed above (Fig. 4), it is unlikely that
biotransformation of precursors can fully explain the PFOS isomer
pattern difference between total exposure and human serum, due to
the low contribution of precursors to total PFOS exposure, which was
estimated to be 16% in the intermediate-exposure scenario (Table S13).
Another process that may alter the PFOS isomer pattern in human
serum relative to the total exposure are isomer-speciﬁc differences in
elimination half-lives between PFOS isomers. Both in rats and humans
the major branched isomers are excreted faster relative to linear PFOS
via urine (Benskin et al., 2009a; Zhang et al., 2013a). If thiswas the dom-
inant elimination route, then the isomer pattern of total PFOS exposure
(estimated as 84% linear)would becomeevenmore enrichedwith linear
PFOS in humans. However, the PFOS elimination half-life calculated
from blood serummeasurements (representing overall human elimina-
tion through all processes) is shorter compared to the half-life estimated
only from urinary excretion (Olsen et al., 2007; Zhang et al., 2013a),
indicating that there may be other signiﬁcant elimination processes for
PFOS, such as faecal excretion. Nevertheless, it is highly unlikely that
isomer-speciﬁc faecal excretion not only compensates for the enrich-
ment of linear isomers in humans through urinary excretion but even
turns PFOS elimination into a process that explains the enrichment of
branched isomers in human serum relative to total exposure.
Based on our ﬁndings, our initial hypothesis that the isomer pattern
of total PFOS exposure can help to explain the isomer pattern found in
human serum is rejected. Furthermore, current knowledge on isomer-
speciﬁc differences in pharmacokinetics and metabolism of PFOS and/
or precursors combinedwith the present data cannot explain the differ-
ence in the isomer pattern of the intake relative to the pattern in human
serum. This discrepancy between PFOS isomer patterns in external and
internal exposure could potentially be explained by: i) inaccurate esti-
mation of the daily exposure (e.g., due to unknown precursors, missingor poorly quantiﬁed exposure pathways and/or poorly quantiﬁed iso-
mer ratios of PFOS and precursors) or ii) an incomplete understanding
of the human pharmacokinetic processes (e.g., biotransformation and
elimination kinetics of precursors, intermediates and PFOS isomers).
3.3. Direct versus indirect exposure to PFCAs
The estimated daily intakes for all PFCAs and individual precursors
(assuming no biotransformation) are provided in Table S11. Based on
these intakes and biotransformation factors for precursors as given in
Section 2.2, the highest total daily exposures among individual PFCAs
are estimated for PFOA with 44 pg/kg/d, 270 pg/kg/d, and 3000 pg/kg/d
for the low-, intermediate-, and high-exposure scenarios, respectively
(Table 1, Fig. 2). Direct PFOA intake is dominant in the low- and
intermediate-exposure scenarios (87% and 73% of total exposure,
respectively), while in the high-exposure scenario precursor-based
(indirect) intake is more important, contributing 64% to the total expo-
sure (Tables S12–S14). Lower daily exposures are estimated for PFHxA
and PFDA, ranging from 15 to 520 pg/kg/d for PFHxA and from 24 to
660 pg/kg/d for PFDA, depending on the exposure scenario (Table 1).
For both PFHxA and PFDA, direct intake is dominant in the low- and
intermediate-exposure scenarios, contributing between 72% and 96%
of the total exposures. In the high-exposure scenario, direct PFHxA in-
take is still dominant (66%), whereas for PFDA themajor daily exposure
(66%) originates from precursor-based intakes. The lowest daily expo-
sures are estimated for PFBA and PFDoDA, ranging between 6.3 and
190 pg/kg/d for PFBA and between 23 and 180 pg/kg/d for PFDoDA, de-
pending on the exposure scenario (Table 1). For both PFBA and PFDoDA,
daily exposures originate almost entirely from direct intakes regardless
of the scenario (i.e., 75%–99%). Based on these results, our hypothesis
that the estimated total exposure to PFOA is greater than to other
PFCA homologues, and that contributions of direct and indirect expo-
sure vary widely by homologue, is veriﬁed. Furthermore, the exposure
scenario has a strong inﬂuence on the estimated relative importance
of direct and indirect intakes, with precursors becoming more impor-
tant the higher the exposure scenario (Table 1).
The relative contributions of each individual intake pathway (direct
or indirect exposure and four different exposure media) to the total
daily exposures are provided in Fig. 3 and Tables S12–S14 for individual
PFCAs. Direct exposure to PFBA via drinking water consumption is esti-
mated to be the primary exposure pathway in all exposure scenarios
(88–99%) (although data on PFBA in other exposure pathways, such
as dietary intake, is limited). Direct exposure via food is estimated to
be the major exposure pathway for PFHxA, PFOA, PFDA and PFDoDA
in the low- (41–88% of total exposure) and intermediate- (38–86%) ex-
posure scenarios. In the high-exposure scenario, direct dietary exposure
is estimated to be the major exposure pathway only for PFHxA and
PFDoDA (42 and 47%, respectively), while for PFOA and PFDA precursor
exposure via dust ingestion is estimated to be the dominant pathway
(62% for both pathways).
Sensitivity analysis reveals that the GI uptake fraction for PFCAs and
diPAPs is the most inﬂuential parameter affecting the calculated total
exposure to all individual PFCAs in all exposure scenarios (Figs. S2–
S6). However, there is a large uncertainty regarding this parameter for
PFCAs as well as for diPAPs (see Section 2.2). For PFBA, the concentra-
tion in water and volume of water consumed are themost sensitive pa-
rameters in all three exposure scenarios after the GI uptake fraction.
These parameters are quite well constrained. For PFHxA, PFOA, PFDA,
and PFDoDA, concentrations in water, food, or air are inﬂuential param-
eters in the low- and intermediate-exposure scenarios, whereas levels
in dust, amount of dust ingested and biotransformation factors for
PAPs become more inﬂuential in the high-exposure scenario. Levels of
individual PFCAs in different exposure media and FTOHs in air can be
measured with a high level of certainty. On the other hand, concentra-
tions of diPAPs in dust, the amount of dust ingested, and biotransforma-
tion factors for diPAPs are poorly constrained.
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been determined for PFOA, and it should be noted that the daily expo-
sure estimates for PFOA in the current study are roughly one order of
magnitude lower for each exposure scenario compared to earlier esti-
mates (Fig. 2) (Trudel et al., 2008; Vestergren et al., 2008). The relative
contribution of precursors to total PFOA exposure is higher in the pres-
ent study in all three exposure scenarios compared to the earlier estima-
tions (Vestergren et al., 2008). These differences between the present
and earlier studies are likely the result of one or several of the following
factors: i) reduced emissions over time and therewith lower levels of
PFOA and its precursors in exposure media (US EPA, 2006; Wang
et al., 2014), ii) improvement of analytical methods resulting in more
accurate (i.e., generally lower) PFOA concentrations in the major expo-
suremedium, food (Vestergren et al., 2012), iii)more literature data be-
came available on PFOA and precursors in the exposure media included
in the present study (e.g., diPAPs were not included in the study by
Vestergren et al. (2008)), and iv) different exposure pathways are
included in the various studies. As for PFOS, our initial hypothesis, that
reexamination of total PFOA exposure with up-to-date data would
result in lower calculated daily exposures, is veriﬁed. This change in
total PFOA exposures is in line with changes observed in temporal
trend monitoring studies. The hypothesis that precursors play a more
important role compared to earlier estimations is accepted for all expo-
sure scenarios. The scarcity of data on uptake and biotransformation fac-
tors for individual PFCAs and their precursors create uncertainties in the
estimations of total human exposure to PFCAs as well as precursor con-
tribution to this exposure. Addressing these knowledge gaps should be
a key priority in future research on human exposure to PFCAs.
3.4. Modelling PFAA levels in human serum from estimated total daily
exposures
Concentrations of PFDA and PFDoDA in human serum cannot be
modelled based on the estimated exposures as serum elimination
half-lives and volumes of distribution for these PFAAs are currently
not available. On the other hand, these parameters are available for
PFBA, PFHxA, PFOA, and PFOS (see Section 2.4). Based on the estimated
daily exposure, the modelled PFBA and PFHxA concentrations in serum
are 0.0039 and 0.014 ng/g, respectively (Fig. 5). Literature data on PFBA
and PFHxA in human serum from European and North American coun-
tries is extremely limited. In human serum from the USA, PFBA and
PFHxA concentrations are higher compared to themodelled serum con-
centrations, which could be due to local high exposure to PFBA and0
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Fig. 5.Modelled (red line) and literature (blue bars) PFBA, PFHxA, PFOA, and PFOS concentrati
trations estimated with the minimum and maximum elimination half-lives. Intermediate-expo
tions in serum are the average (±SD, if provided) of reported concentrations in samples th
et al., 2012; 4Fisher et al., 2013; 5Glynn et al., 2012; 6Nordström Joensen et al., 2013; 7Yeung
10Ji et al., 2012; 11Okada et al., 2013; 12Yamaguchi et al., 2013).PFHxA in the USA study, or incorrect model parameterization for these
substances. The modelled PFOA concentration in serum based on total
daily PFOA exposure ranges between 1.9 and 3.2 ng/g, which is in
good agreement with concentrations reported in serum samples,
although there were some studies reporting on higher PFOA concentra-
tions (Fig. 5). Based on the estimated total daily PFOS exposure, the
modelled concentration ranges between 4.0 and 5.1 ng/g. This is gener-
ally lower compared to the measured concentrations in serum samples
collected during and after 2007 in North America, Europe and Asia
(Fig. 5). The reported higher PFOS levels in serum samples relative to
the modelled concentrations can be explained by the long elimination
half-lives of PFOS in humans (i.e., serum contains PFOS derived from
historic exposure) (Section 2.4) together with the decreasing temporal
trends in exposure media such as food items (Johansson et al., 2014)
and in human serum (e.g., Glynn et al., 2012). Other factors could be
that uptake and biotransformation factors are underestimated or that
certain populations are (locally) more exposed to PFAAs and precursors
than was estimated using the available literature data. The measured
PFAA concentrations in serum between 2007 and 2011 originate partly
from exposure prior to 2007, which was likely higher compared to the
exposure post 2007 estimated in the present study. The decrease in
human serum is steeper for PFOS compared to PFOA, thus a larger dis-
crepancy between modelled and measured levels is expected and also
observed for PFOS (Fig. 5). In fact, Glynn et al. (2012) reported PFOS
and PFOA concentrations in serum in 2010 (originating largely from ex-
posure 2007–2010) of 6.8 and 1.7 ng/g, respectively, which are close to
the modelled serum concentrations. Thus, despite the uncertainties in
the estimation of daily exposures (see sections above) and additional
uncertainties in the modelling such as the volumes of distribution and
elimination half-lives, a good match was obtained between modelled
and measured values for both PFOS and PFOA. This lends conﬁdence
in our values for daily exposures and the estimated relative contribution
of precursor intake to total PFAA exposure.
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